Advancing Structural Biology with leadXpro

Membrane proteins are the living cell’s connection to the outside world. They are extremely important both in health and disease. Despite representing only around one-fourth of the human proteome, they are targeted by more than half of existing drugs. At the same time, membrane proteins are notoriously difficult to work with in the laboratory, with their intrinsic instability and low expression levels making them hard to study.

To address this problem, Orbion and leadXpro AG are joining forces. Our research collaboration will explore the potential of Orbion’s existing and new Astra AI models to provide actionable insights to further enhance leadXpro’s platform for tackling challenging membrane proteins. On the leadXpro side, the collaboration is led by Dr. Robert, Kin Yip Cheng (Head of Biochemistry) and Dr. Michael Hennig (CEO of leadXpro).

This collaboration showcases Orbion’s dedication to providing real, useful guidance for protein work and leadXpro’s commitment to incorporate machine learning in its technology platform. We want to support researchers in overcoming technical hurdles and focus on scientific progress – we are excited to see what we can achieve together!

leadXpro’s comment:
Membrane proteins remain some of the hardest drug targets to study. Producing high-quality proteins for biophysics and structure research is our passion and mission. We further enhance our technology platform by merging our existing expertise with Orbion’s machine learning pipeline in protein science and seek to leverage the combined expertise to accelerate drug discovery research and unlock tomorrow’s medicine.

Orbion's comment:
When a challenge touches billions of lives, the stakes skyrocket. Membrane proteins are just that: barely 10% are drugged because of their volatility. At Orbion, hard never means impossible - it just takes the right people and partners. By joining leadXpro’s structural biology brilliance with our predictive machine learning pipeline, we’ll bring clarity to membrane proteins and unlock next generation drugs for today’s unknown diseases.